Literature DB >> 12188955

Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence.

M Levent Deniz1, Türker Kiliç, Idil Almaata, Ozlem Kurtkaya, Aydin Sav, M Necmettin Pamir.   

Abstract

OBJECTIVE: To test the hypothesis that the expression of certain growth factors and/or structural proteins is correlated with the biological behavior of cranial base chordomas.
METHODS: The study investigated 14 pathological specimens of cranial base chordomas from patients who were monitored for at least 2 years after their initial operations. Some cases involved multiple tumor recurrences and multiple operations. For those patients, the time to recurrence after each operation was recorded and a mean value was calculated. Nine patients with mean times to recurrence of 24 months or more or with 24 months of follow-up monitoring without recurrence after single operations were designated the "good-prognosis" group. Five patients with mean times to recurrence of less than 24 months were designated the "poor-prognosis" group. In each case, only the specimen from the initial operation was studied. Multiple sequential sections were cut from paraffin-embedded blocks of tissue and immunohistochemically prepared for detection of three growth factors and three structural proteins, i.e., basic fibroblast growth factor, transforming growth factor alpha, vascular endothelial growth factor, fibronectin, collagen III, and collagen IV. Intensity of expression was graded by using a four-tier system (Grades 0, 1, 2, and 3). Levels of expression of the molecules in the two groups were evaluated and compared.
RESULTS: The mean transforming growth factor alpha expression intensity grades for the good- and poor-prognosis groups were 0.8 and 2.6, respectively, and the corresponding mean basic fibroblast growth factor grades were 1.4 and 2.6. For both groups, the mean grade for vascular endothelial growth factor expression was 0.6. For fibronectin, the mean staining grades for the good- and poor-prognosis groups were 2.2 and 3.0, respectively. The corresponding mean intensities for collagen III were 1.1 and 0.8, and those for collagen IV were 2.5 and 2.6.
CONCLUSION: Our descriptive data from immunohistochemical analyses of chordomas suggest that high levels of transforming growth factor alpha and basic fibroblast growth factor expression are linked to higher rates of recurrence. Strong fibronectin expression may also be a marker of aggressive biological behavior.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12188955

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  15 in total

1.  Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.

Authors:  R Akhavan-Sigari; M R Gaab; V Rohde; A Brandis; H Tezval; M Abili; K von Eckardstein; H Ostertag
Journal:  Neurosurg Rev       Date:  2013-09-03       Impact factor: 3.042

Review 2.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

3.  The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.

Authors:  Yunping Hu; Akiva Mintz; Sagar R Shah; Alfredo Quinones-Hinojosa; Wesley Hsu
Journal:  Carcinogenesis       Date:  2014-01-20       Impact factor: 4.944

4.  Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.

Authors:  Kang-Wu Chen; Hui-Lin Yang; Jian Lu; Gen-Lin Wang; Yi-Ming Ji; Gui-Zhong Wu; Li-Fan Zhu; Jia-Yong Liu; Xiao-Qing Chen; Yong-Ping Gu
Journal:  J Neurooncol       Date:  2010-06-15       Impact factor: 4.130

Review 5.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

6.  MGMT promoter methylation status in clival chordoma.

Authors:  Gianluca Marucci; Luca Morandi; Diego Mazzatenta; Giorgio Frank; Ernesto Pasquini; Maria Pia Foschini
Journal:  J Neurooncol       Date:  2014-04-26       Impact factor: 4.130

7.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

8.  Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas.

Authors:  Nunung Nur Rahmah; Keiichi Sakai; Jun Nakayama; Kazuhiro Hongo
Journal:  Neurosurg Rev       Date:  2009-10-28       Impact factor: 3.042

9.  Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Authors:  Mauro Longoni; Francesca Orzan; Michela Stroppi; Nicola Boari; Pietro Mortini; Paola Riva
Journal:  Neuro Oncol       Date:  2007-12-19       Impact factor: 12.300

Review 10.  The molecular aspects of chordoma.

Authors:  Sukru Gulluoglu; Ozlem Turksoy; Aysegul Kuskucu; Ugur Ture; Omer Faruk Bayrak
Journal:  Neurosurg Rev       Date:  2015-09-12       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.